Investigating imaging network markers of cognitive dysfunction and pharmacoresistance in newly diagnosed epilepsy: a protocol for an observational cohort study in the UK. Issue 10 (16th October 2019)

• Record Type: Journal Article
• Authors: de Bézenac, Christophe; Garcia-Finana, Marta; Baker, Gus; Moore, Perry; Leek, Nicola; Mohanraj, Rajiv; Bonilha, Leonardo; Richardson, Mark; Marson, Anthony Guy; Keller, Simon
• Is Part Of: BMJ open. Volume 9:Issue 10(2019)
• Publication Date: 2019-10-16
• Subjects: newly diagnosed -- epilepsy -- brain connectivity -- neuropsychology -- inflammation; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-034347
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Epilepsy is one of the most common serious brain disorders, characterised by seizures that severely affect a person's quality of life and, frequently, their cognitive and mental health. Although most existing work has examined chronic epilepsy, newly diagnosed patients present a unique opportunity to understand the underlying biology of epilepsy and predict effective treatment pathways. The objective of this prospective cohort study is to examine whether cognitive dysfunction is associated with measurable brain architectural and connectivity impairments at diagnosis and whether the outcome of antiepileptic drug treatment can be predicted using these measures. Methods and analysis: 107 patients with newly diagnosed focal epilepsy from two National Health Service Trusts and 48 healthy controls (aged 16–65 years) will be recruited over a period of 30 months. Baseline assessments will include neuropsychological evaluation, structural and functional Magnetic Resonance Imaging (MRI), Electroencephalography (EEG), and a blood and saliva sample. Patients will be followed up every 6 months for a 24-month period to assess treatment outcomes. Connectivity- and network-based analyses of EEG and MRI data will be carried out and examined in relation to neuropsychological evaluation and patient treatment outcomes. Patient outcomes will also be investigated with respect to analysis of molecular isoforms of high mobility group box-1 from blood and saliva samples. Ethics and dissemination: This study was approved by the North West, Liverpool East Research Ethics Committee (19/NW/0384) through the Integrated Research Application System (Project ID 260623). Health Research Authority (HRA) approval was provided on 22 August 2019. The project is sponsored by the UoL (UoL001449) and funded by a UK Medical Research Council (MRC) research grant (MR/S00355X/1). Findings will be presented at national and international meetings and conferences and published in peer-reviewed journals. Trial registration number: IRAS Project ID 260623.